TY - JOUR
T1 - Ras-mutant cancer cells display B-Raf binding to ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase a phosphorylation
AU - Li, Yanping
AU - Takahashi, Maho
AU - Stork, Philip J.S.
PY - 2013/9/20
Y1 - 2013/9/20
N2 - The small G protein Ras regulates proliferation through activation of the mitogen-activated protein (MAP) kinase (ERK) cascade. The first step of Ras-dependent activation of ERK signaling is Ras binding to members of the Raf family of MAP kinase kinase kinases, C-Raf and B-Raf. Recently, it has been reported thatin melanoma cells harboring oncogenic Ras mutations, B-Raf does not bind to Ras and does not contribute to basal ERK activation. For other types of Ras-mutant tumors, the relative contributions of C-Raf and B-Raf are not known. We examined non-melanoma cancer cell lines containing oncogenic Ras mutations and express both C-Raf and B-Raf isoforms, including the lung cancer cell line H1299 cells. Both B-Raf and C-Raf were constitutively bound to oncogenic Ras and contributedtoRas-dependent ERK activation. Ras bindingto B-Raf and C-Raf were both subject to inhibition by the cAMP-dependent protein kinase PKA. cAMP inhibited the growth of H1299 cells and Ras-dependent ERK activation via PKA. PKA inhibited the binding of Ras to both C-Raf and B-Raf through phosphorylations of C-Raf at Ser-259 and B-Raf at Ser-365, respectively. These studies demonstrate thatinnon-melanocytic Ras-mutant cancer cells, Ras signalingtoB-Rafis a significant contributor to ERK activation and that the B-Raf pathway, like that of C-Raf, is a target for inhibition by PKA. We suggest that cAMP and hormones coupled to cAMP may prove useful in dampening the effects of oncogenic Ras in non-melanocytic cancer cells through PKA-dependent actions on B-Raf as well as C-Raf.
AB - The small G protein Ras regulates proliferation through activation of the mitogen-activated protein (MAP) kinase (ERK) cascade. The first step of Ras-dependent activation of ERK signaling is Ras binding to members of the Raf family of MAP kinase kinase kinases, C-Raf and B-Raf. Recently, it has been reported thatin melanoma cells harboring oncogenic Ras mutations, B-Raf does not bind to Ras and does not contribute to basal ERK activation. For other types of Ras-mutant tumors, the relative contributions of C-Raf and B-Raf are not known. We examined non-melanoma cancer cell lines containing oncogenic Ras mutations and express both C-Raf and B-Raf isoforms, including the lung cancer cell line H1299 cells. Both B-Raf and C-Raf were constitutively bound to oncogenic Ras and contributedtoRas-dependent ERK activation. Ras bindingto B-Raf and C-Raf were both subject to inhibition by the cAMP-dependent protein kinase PKA. cAMP inhibited the growth of H1299 cells and Ras-dependent ERK activation via PKA. PKA inhibited the binding of Ras to both C-Raf and B-Raf through phosphorylations of C-Raf at Ser-259 and B-Raf at Ser-365, respectively. These studies demonstrate thatinnon-melanocytic Ras-mutant cancer cells, Ras signalingtoB-Rafis a significant contributor to ERK activation and that the B-Raf pathway, like that of C-Raf, is a target for inhibition by PKA. We suggest that cAMP and hormones coupled to cAMP may prove useful in dampening the effects of oncogenic Ras in non-melanocytic cancer cells through PKA-dependent actions on B-Raf as well as C-Raf.
UR - http://www.scopus.com/inward/record.url?scp=84884561095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884561095&partnerID=8YFLogxK
U2 - 10.1074/jbc.M113.463067
DO - 10.1074/jbc.M113.463067
M3 - Article
C2 - 23893412
AN - SCOPUS:84884561095
SN - 0021-9258
VL - 288
SP - 27646
EP - 27657
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 38
ER -